Search results.

Cagrilintide and semaglutide are different peptide medicines and are not interchangeable. Cagrilintide is an investigational long-acting amylin analogue in the standalone RENEW Phase 3 program. Semaglutide is a GLP-1 receptor agonist with product-specific approvals, including WEGOVY for chronic weight management in defined populations. REDEFINE 1 randomized separate cagrilintide and semaglutide arms under one protocol and reported higher descriptive mean weight loss with semaglutide, but the cited sources do not establish a prespecified, statistically powered superiority test between those two monotherapy arms. Cagrilintide is not FDA approved and has no approved retail product or commercial price.

CagriSema and semaglutide were compared directly in the randomized Phase 3 REDEFINE 1 trial, which makes this comparison stronger than placing results from unrelated studies side by side. At 68 weeks, the trial-product estimand reported 22.7% mean weight loss with CagriSema and 16.1% with semaglutide. The same protocol used flexible dose escalation and compared CagriSema 2.4 mg/2.4 mg with semaglutide 2.4 mg in adults with obesity or overweight without type 2 diabetes. Those group results do not predict an individual winner. CagriSema remains investigational with an FDA application under review, while WEGOVY is an FDA-approved semaglutide product with product-specific labels and presentations.

Ecnoglutide and semaglutide are GLP-1 receptor agonists with different product and regulatory records. A direct randomized open-label Phase 2 study in 163 Chinese adults with obesity reported mean weight changes of 12.8% with ecnoglutide and 9.5% with semaglutide at week 20, with both groups using 2.4 mg maintenance doses. That is direct interim evidence for one protocol, not a universal winner claim. Ecnoglutide is approved in China for chronic weight management and type 2 diabetes but is not FDA approved. WEGOVY is an FDA-approved semaglutide product with its own label, forms, indications, and safety record.

Foundayo and Wegovy are FDA-approved US weight-management products that activate the GLP-1 receptor, but they are not the same kind of drug and have not been compared in a randomized head-to-head trial. Foundayo contains orforglipron, a once-daily non-peptide small-molecule tablet. Wegovy contains the peptide semaglutide and its current US label includes both a once-daily 25 mg tablet and once-weekly injections. The Foundayo label reports about 11.1% mean weight reduction at 72 weeks for its highest approved equivalent-dose group, while the Wegovy tablet label reports 13.6% at 64 weeks. Those values come from separate protocols and do not prove that either product is superior.

Semaglutide and retatrutide have not been compared in a randomized head-to-head trial. Semaglutide is a GLP-1 receptor agonist used in several product-specific approved medicines, including WEGOVY under FDA application NDA 215256. Retatrutide is Lilly's investigational once-weekly GIP, GLP-1, and glucagon receptor triple agonist and is not FDA approved. WEGOVY and STEP evidence and retatrutide's 80-week TRIUMPH-1 result come from separate programs, populations, doses, durations, comparators, and statistical analyses. Those results can explain each evidence record, but they cannot prove that retatrutide is better, safer, more durable, or appropriate for an individual.

FDA-approved incretin medicine. Injection and tablets · Subcutaneous and oral. NDA 215256 · FDA-approved prescription drug.

Cagrilintide and CagriSema are related but not the same investigational treatment. Cagrilintide is a long-acting amylin analogue studied on its own. CagriSema is a fixed-dose combination of cagrilintide and semaglutide, a GLP-1 receptor agonist. REDEFINE 1 included separate randomized arms for cagrilintide alone and the combination. Novo Nordisk has submitted CagriSema to the FDA, while standalone cagrilintide continues in the RENEW Phase 3 program. Neither is currently FDA approved.

Obesity and metabolic pipeline. Amylin analogue + GLP-1 receptor agonist · Once-weekly subcutaneous injection. 30 matched ClinicalTrials.gov records with status, phase, posted-results, country, US state, and site-level recruitment context.

CagriSema and retatrutide are advanced but different investigational obesity drugs, and no head-to-head trial has compared them. CagriSema combines cagrilintide with semaglutide in a once-weekly injection and has been submitted to the FDA. Retatrutide is a once-weekly triple agonist targeting GIP, GLP-1, and glucagon receptors and has reported Phase 3 topline results. CagriSema is not approved merely because an application was filed, retatrutide is not approved, and separate trial percentages cannot determine which drug is better.

CagriSema and survodutide are different investigational once-weekly obesity drugs with no head-to-head trial. CagriSema combines cagrilintide and semaglutide to engage amylin and GLP-1 pathways and is under FDA review. Survodutide is a single glucagon and GLP-1 receptor dual agonist with Phase 3 obesity and liver-focused evidence. Both have reported Phase 3 weight results, but only CagriSema has a publicly documented US application under review at this evidence check. Neither is approved for marketing, and their separate trials cannot establish which program is better.

MariTide and CagriSema are different investigational obesity programs with no head-to-head trial. MariTide is Amgen's peptide-antibody conjugate that activates GLP-1 receptors and antagonizes GIP receptors, with monthly dosing at the center of its efficacy program. CagriSema is Novo Nordisk's once-weekly combination of cagrilintide and semaglutide, engaging amylin and GLP-1 pathways. CagriSema has completed pivotal Phase 3 trials and is under FDA review. MariTide has Phase 2 efficacy evidence and an active Phase 3 program. Neither is FDA approved.

Search 268 ClinicalTrials.gov records across 13 peptide and next-generation weight-loss programs by status, phase, country, US state, city, postal code, sponsor, intervention, alias, or NCT ID.

Amycretin, now called zenagamtide, and CagriSema are separate Novo Nordisk programs that both combine GLP-1 and amylin biology, but they have not been compared head to head. Zenagamtide is one investigational molecule being developed as a daily tablet and a weekly injection. CagriSema is a weekly fixed-dose injection containing two molecules, cagrilintide and semaglutide. CagriSema has completed pivotal Phase 3 trials and is under FDA review, while zenagamtide's current evidence is earlier and its Phase 3 development is underway. Neither is FDA approved.

Compare semaglutide with CagriSema, retatrutide, ecnoglutide, and other metabolic programs while preserving direct-trial, product, regulatory, and ClinicalTrials.gov registry boundaries.